SynthesisThe Journal of clinical endocrinology and metabolism2020
Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
Synthesis in The Journal of clinical endocrinology and metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04664036 (Prevalence, Incidence and Characteristics of NAFLD/NASH in Type 1 Diabetes Mellitus Obtained Via a Non-invasive Screening Protocol), which is not on this map. Cited by 80 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prevalence, Incidence and Characteristics of NAFLD/NASH in Type 1 Diabetes Mellitus Obtained Via a Non-invasive Screening Protocol
Who cites it
80 citing papers in PubMed, 2 syntheses or guidelines pooled it, 140 citations in OpenAlex.
- Risk Factors Related to the Development of Nonalcoholic Fatty Liver: A Systematic Review.Canadian journal of gastroenterology & hepatology · 2025Pooled it
- Risk of dementia or cognitive impairment in non-alcoholic fatty liver disease: A systematic review and meta-analysis.Frontiers in aging neuroscience · 2022Pooled it
- Liver fibrosis risk: a silent threat in type 1 diabetes mellitus.Journal of endocrinological investigation · 2026Article
- Obesity in Adults with Type 1 Diabetes Mellitus.Journal of obesity & metabolic syndrome · 2026Review
- MASLD, diabetes and PMOS across the female life stages.Diabetologia · 2026Review
- Metabolic dysfunction and the use of adjunct medications in type 1 diabetes.Current opinion in endocrinology, diabetes, and obesity · 2026Review
- Prevalence and Risk Factors of Celiac Disease in Patients With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis.JGH open : an open access journal of gastroenterology and hepatology · 2026Review
- Glucagon-like peptide-1 receptor agonists for major cardiovascular and kidney outcomes in type 1 diabetes.Nature medicine · 2026Article
- Autoimmune disease in offspring of mothers with metabolic dysfunction-associated steatotic liver disease (MASLD): a nationwide cohort study.Scientific reports · 2026Article
- High prevalence of metabolic comorbidities in Asian children with type 1 diabetes and obesity.Annals of pediatric endocrinology & metabolism · 2026Article
- Liver fat content is not elevated in people with type 1 diabetes: the Maastricht Study.Diabetologia · 2026Article
- Non-invasive risk stratification of metabolic dysfunction-associated steatotic liver disease and liver fibrosis in adults with type 1 diabetes.Frontiers in endocrinology · 2026Observational
- 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026.Diabetes care · 2026Review
- Coronary artery calcification in type 1 diabetes after 10-year ketogenic diet.Journal of applied physiology (Bethesda, Md. : 1985) · 2025Article
- Identification and verification of feature biomarkers associated with CD14Journal of diabetes investigation · 2025Article
- Characterizing plasma lipid species in metabolic dysfunction associated steatotic liver disease in persons with type 1 diabetes.Scientific reports · 2025Article
- Cohort profile of the Heidelberg study on diabetes and complications HEIST-DiC.Scientific reports · 2025Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease in People with Type 1 Diabetes.Journal of clinical medicine · 2025Review
- Prevalence of liver disorders in children and adolescents with type 1 diabetes mellitus.BMC pediatrics · 2025Article
- Insulin Resistance in Type 1 Diabetes: Concepts and Implications for Therapy.Journal of diabetes · 2025Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextNonalcoholic fatty liver disease (NAFLD) prevalence is high, especially in patients with obesity and type 2 diabetes, and is expected to rise steeply in the coming decades.
objectiveWe estimated NAFLD prevalence in patients with type 1 diabetes and explored associated characteristics and outcomes. DATA SOURCES: We reviewed PubMed and Embase for studies on NAFLD and type 1 diabetes to March 2020. We screened references of included articles. STUDY SELECTION: Two authors independently screened titles/abstracts. One author screened full text articles. NAFLD was defined as described in the individual studies: steatosis and/or fibrosis. Studies not reporting alternative causes of hepatic steatosis or defining NAFLD only as elevated liver enzymes, were excluded. Initially, 919 articles met the selection criteria. DATA EXTRACTION: One researcher performed data extraction and risk of bias assessment using standardized tables. DATA SYNTHESIS: We assessed pooled prevalence rates by meta-analysis using a random-effects model, subsequently exploring heterogeneity by subgroup-, meta-regression-, and sensitivity analysis. Twenty studies between 2009 and 2019 were included (n = 3901). Pooled NAFLD prevalence was 19.3% (95% CI, 12.3%-27.5%), increasing to 22.0% (95% CI, 13.9%-31.2%) in adults only. Pooled prevalence of ultrasound studies was high (27.1%, 95% CI, 18.7%-36.3%) compared to studies using magnetic resonance imaging (8.6%, 95% CI, 2.1%-18.6%), liver biopsy (19.3%, 95% CI, 10.0%-30.7%), or transient elastography (2.3%, 95% CI, 0.6%-4.8%).
conclusionNAFLD prevalence in patients with type 1 diabetes is considerable and is highly dependent on the specific diagnostic modality and NAFLD definition used. These data are helpful in directing actions to standardize NAFLD diagnosis, which will help defining contributing mechanisms and outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.